Extent of use of immediate-release formulations of calcium channel blockers as antihypertensive monotherapy by primary care physicians: Multicentric study from Bahrain

Journal of Postgraduate Medicine

Volumn 48, Issue 3, 2002, Pages 172-175

  Sequeira, R P ^a   Jassim Al Khaja, K A ^a   Mathur, V S ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Antihypertensive monotherapy; Calcium channel blockers; Immediate release formulations; Prescribing pattern; Primary care

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; METHYLDOPA; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; VERAPAMIL;

ADULT; AGE; AGED; ARTICLE; BAHRAIN; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC HYPERTENSION; DRUG FORMULATION; DRUG SAFETY; GENERAL PRACTITIONER; HEALTH CENTER; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; REGISTER; RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BAHRAIN; CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION REVIEW; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0036662837     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Guideline Subcommittee, World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;7:151-83.
2. Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal. Drugs 1998;55:509-17.
3. Alderman MH, Cohen H, Rocque R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997;349:594-8.
4. Al Khaja KAJ, Sequeira RP, Mathur VS. Patterns of utilization of antihypertensive drug combinations in Bahrain: do they conform with international guidelines? Intl J Clin Pharmacol Ther 2000; 38:568-80.
5. Robertson JIS. Which antihypertensive drug classes have been shown to be beneficial? What are the benefits? A critique of hypertension treatment trials. Cardiovasc Drugs Therap 2000;14:357-66.
6. Chan JCN, Ko GTC, Leung DHY, Cheung RCK, Cheung MYF, So WY, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Intl 2000;57:590-600.
7. Furberg CD, Psaty BM, Meyer JV. Nifedipine dose-related increase in mortality with coronary heart disease. Circulation 1995;92:1326-31.
8. Ruzicka M, Leenen FH. Relevance of intermittent increase in sympathetic activity for adverse outcome on short-acting calcium antagonists. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press; 1995. p. 2815-25.
9. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. J Am Med Assoc 1995;274:620-5.
10. Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43:1191-97.
11. Yousuf S. Calcium antagonists in coronary artery disease and hypertension. Time for re-evaluation? Circulation 1995;92:1079-82.
12. Stason WB, Schmid CA, Niedzwiecki D, Whiting GW, Caubet JF, Cory D, et al. Safety of nifedipine in angina pectoris. A meta-analysis. Hypertension 1999;33:24-31.
13. Barnett AA. FDA Committee rules calcium channel blockers safe. Lancet 1996;377:13.
14. The National Heart, Lung and Blood Institute (NHLBI). New analysis regarding the safety of calcium channel blockers: a statement for health professionals from the National Heart, Lung and Blood Institute, September 1995, NHLBI:MD, USA.